{"id":5167,"date":"2021-02-23T08:54:10","date_gmt":"2021-02-23T08:54:10","guid":{"rendered":"https:\/\/techclot.com\/index.php\/2021\/02\/23\/molecular-stethoscope-announces-publication-of-its-nafld-nash-study-in-the-american-journal-5\/"},"modified":"2021-02-23T08:54:10","modified_gmt":"2021-02-23T08:54:10","slug":"molecular-stethoscope-announces-publication-of-its-nafld-nash-study-in-the-american-journal-5","status":"publish","type":"post","link":"https:\/\/techclot.com\/index.php\/2021\/02\/23\/molecular-stethoscope-announces-publication-of-its-nafld-nash-study-in-the-american-journal-5\/","title":{"rendered":"Molecular Stethoscope Announces Publication of its NAFLD\/NASH Study in the American Journal …"},"content":{"rendered":"

Molecular Stethoscope Announces Publication of its NAFLD\/NASH Study in the American Journal …<\/a><\/p>\n

Circulating cell-free mRNA in blood reflective of NAFLD\/NASH liver pathology<\/b><\/p>\n

PALO ALTO, Calif.<\/span>, Feb. 23, 2021<\/span> \/PRNewswire\/ — Molecular Stethoscope, Inc., a precision medicine biotechnology company, announces publication of its human proof-of-concept study describing the stratification of NAFLD\/NASH patients with clinically relevant and advanced liver fibrosis using the company’s Next-Generation cell-free mRNA Liquid Biopsy Technology Platform. The study titled “Non-invasive Stratification of Non-Alcoholic Fatty Liver Disease by Whole-transcriptome Cell-free mRNA Characterization” was published in the American Journal of Physiology<\/i> – Gastrointestinal and Liver Physiology<\/i>, a journal of the American Physiological Society. The first author is Naga Chalasani, M.D., Professor of Gastroenterology and Hepatology and Interim Chair in the Department of Medicine at Indiana University<\/span> in the USA<\/span>. Dr. Chalasani is the leading author of the AASLD Practice Guidelines for the diagnosis and management of NAFLD\/NASH disease. “Once validated in larger studies, non-invasive Liquid Biopsy diagnostic solutions such as the ones being developed by Molecular Stethoscope may be used serially not only as Drug Development Tools to monitor the ongoing challenging pharmacotherapy clinical trials, but also to follow cf-mRNA changes during lifestyle modification which has led to marked improvements in steatosis and fibrosis,” commented Dr. Chalasani. <\/p>\n

There continues to be a concerted effort to accelerate the translation of innovative technologies to clinical studies and patient management. Consistent with this, the diligent efforts by the USA<\/span> National Institute of Standards and Technology (NIST), biotechnology consortia and the USA<\/span>-FDA have made foundational strides in establishing best practice Next Generation Sequencing, RNA-Seq and Machine Learning that will accelerate the translation of the Molecular Stethoscope Technology Platform into products for clinical practice.<\/p>\n

The substantial unmet clinical need in NAFLD\/NASH has spurred a $1.4B<\/span> investment by numerous Pharma\/Biotech companies with 125 interventional clinical trials now recruiting subjects. In addition, the USA<\/span>-FDA has encouraged the development of Drug Development Tools to monitor efficacy of pharmacotherapies that target multiple mechanisms of action. “Clinical interventional studies for NAFLD\/NASH have multiple challenges. The Liver Forum, a collaborative non-competitive group of stakeholders from academia, regulatory agencies, professional societies, patient organizations, and industry stakeholders, has recommended standard reporting of baseline parameters and standardization of diet and exercise information to facilitate cross-trial analysis, an important step in validation of Non-Invasive Tests for this serious common chronic liver disease,” added Veronica Miller<\/span>, Ph.D., the founder and Director of the Forum for Collaborative Research and a Professor (Adjunct) at the UC Berkeley School of Public Health.<\/p>\n

“The publication of this important study positions us to move forward with the next phase of product development to have a significant impact on NAFLD\/NASH clinical practice and in Pharma\/Biotech R&D to improve the health of patients,” commented Guillermo Elias<\/span>, Ph.D., Chief Executive Officer at Molecular Stethoscope.<\/p>\n

The study is available at the American Journal of Physiology<\/i> – Gastrointestinal and Liver Physiology<\/i> website.<\/p>\n

https:\/\/journals.physiology.org\/doi\/abs\/10.1152\/ajpgi.00397.2020<\/a><\/p>\n

“We would like to thank the contributions of our medical and scientific collaborators and NAFLD\/NASH patients for participating in this study,” acknowledged Dr. Elias, CEO of Molecular Stethoscope.<\/p>\n

About Molecular Stethoscope
Molecular Stethoscope is a precision medicine company based in Silicon Valley, California<\/span>, focused on discovering, developing and commercializing non-invasive and dynamic products for the early detection, diagnosis and treatment-response monitoring of chronic diseases starting with the liver (NAFLD\/NASH) and the central nervous system (Alzheimer’s Disease and Multiple Sclerosis). Molecular Stethoscope was co-founded by Dr. Stephen Quake, Professor of Bioengineering at Stanford University<\/span>, and co-President of the Chan Zuckerberg BioHub, and Dr. Eric Topol<\/span>, Director and Founder, Scripps Research Translational Institute; Chair of Innovative Medicine, Scripps. The Company’s proprietary and novel Next-Generation cf-mRNA Liquid Biopsy-Artificial Intelligence Technology Platform integrates cell-free mRNA (cf-mRNA) with RNA-Seq, clinical information, and purpose-built bioinformatics and machine learning and artificial intelligence to generate clinically actionable, dynamic information to fundamentally change how healthcare is delivered at scale.<\/p>\n

Forward Looking Statement
This press release contains forward-looking statements including, but not limited to statements about the Company’s expectations regarding its proprietary Technology Platform. Forward looking statements are subject to uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements.<\/p>\n

Additional information and inquiries<\/p>\n

Investor Relations: investorrelations@molecularstethoscope.com<\/a><\/p>\n

Public and Media Relations: publicrelations@molecularstethoscope.com<\/a><\/p>\n

Logo – https:\/\/mma.prnewswire.com\/media\/353332\/Molecular_Stethoscope_Inc_Logo.jpg<\/a>  <\/p>\n

<\/p>\n

Related Links<\/h4>\n

http:\/\/www.molecularstethoscope.com<\/a>
<\/p>\n

SOURCE Molecular Stethoscope, Inc.<\/p>\n<\/p>\n

Published at Tue, 23 Feb 2021 07:52:30 +0000<\/p>\n

BBVA and Google Cloud Form Strategic Partnership to Drive Security Innovation in Financial …<\/a><\/p>\n

MADRID<\/span> and SUNNYVALE, Calif.<\/span>, Feb. 23, 2021<\/span> \/PRNewswire\/ — BBVA and Google Cloud today announced a new strategic partnership to transform the bank’s security strategy by optimizing and improving its security infrastructure. As part of this global agreement, BBVA will collaborate with Google Cloud in the development of groundbreaking new artificial intelligence (AI) and machine learning (ML) models to predict and prevent cyberattacks against its banking infrastructure, providing a more secure experience for the bank and its customers. <\/p>\n

BBVA is the first bank in Europe<\/span> to deploy Chronicle<\/a><\/u>, Google Cloud’s security analytics platform that allows teams to store and analyze all their security data in one place to detect and investigate threats at scale. BBVA will incorporate Google Cloud\u00b4s innovative artificial intelligence capabilities into its security strategy and shape its “Security Operations Center (SOC) of the Future.” <\/p>\n

In this centre, Google Cloud and BBVA will work to jointly develop a new platform that will allow the bank to adopt a more advanced technology by placing it in a more cost-effective environment, and with greater scalability. The use of Google Cloud’s Chronicle, combined with the expertise of BBVA’s security operations departments, will enable the bank to leverage best-in-class AI capabilities to prevent cyberattacks.<\/p>\n

“This partnership represents a leap forward for the bank, and allows us to be at the forefront in preventing threats to the security of our financial infrastructure and our clients,” said \u00c1lvaro Garrido,<\/a><\/u> Chief Security Officer, BBVA. “The platform surprised us in its ability to quickly and accurately mitigate possible threats. Google Cloud’s Chronicle meets our expectations and will be a magnificent partner in the transformation of our security posture, just as Google Cloud has been in other areas of the bank.”<\/p>\n

“The Chronicle platform was built to help companies like BBVA improve its security infrastructure, leveraging the speed and scalability of Google Cloud’s technology,” said Derek White<\/span>, VP Global Financial Services Industry, Google Cloud. “This collaboration will solidify Chronicle as one of the key pillars of BBVA’s security infrastructure and will support its strategy in offering its customers a trusted approach to products and services.”<\/p>\n

BBVA has collaborated with Google Cloud to digitally transform its operations since 2011.  BBVA is using Google Workspace,<\/a><\/u> along with other services from Google Cloud, to promote a new, safe, and more agile collaborative way of working among its employees. These tools allow for global collaboration, without putting the information and documentation generated at risk.<\/p>\n

About Google Cloud
<\/b>Google Cloud provides organizations with leading infrastructure, platform capabilities and industry solutions. We deliver enterprise-grade cloud solutions that leverage Google’s cutting-edge technology to help companies operate more efficiently and adapt to changing needs, giving customers a foundation for the future. Customers in more than 150 countries turn to Google Cloud as their trusted partner to solve their most critical business problems.<\/p>\n

About BBVA <\/b>  
<\/b>BBVA is a customer-centric global financial services group founded in 1857. The Group has a strong leadership position in the Spanish market, is the largest financial institution in Mexico<\/span>, it has leading franchises in South America<\/span> and the Sunbelt Region of the United States<\/span>. It is also the leading shareholder in Turkey’s<\/span> Garanti BBVA. Its purpose is to bring the age of opportunities to everyone, based on our customers’ real needs: provide the best solutions, helping them make the best financial decisions, through an easy and convenient experience. The institution rests in solid values: Customer comes first, we think big and we are one team. Its responsible banking model aspires to achieve a more inclusive and sustainable society.<\/p>\n

SOURCE Google Cloud<\/p>\n

<\/p>\n

Published at Tue, 23 Feb 2021 07:52:30 +0000<\/p>\n","protected":false},"excerpt":{"rendered":"

Molecular Stethoscope Announces Publication of its NAFLD\/NASH Study in the American Journal … Circulating cell-free…<\/p>\n","protected":false},"author":3,"featured_media":2336,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-5167","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized"],"jetpack_featured_media_url":"https:\/\/i0.wp.com\/techclot.com\/wp-content\/uploads\/2020\/08\/4G1jb9.jpg?fit=500%2C325&ssl=1","jetpack_sharing_enabled":true,"jetpack_shortlink":"https:\/\/wp.me\/p3orZX-1ll","jetpack-related-posts":[],"_links":{"self":[{"href":"https:\/\/techclot.com\/index.php\/wp-json\/wp\/v2\/posts\/5167","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/techclot.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/techclot.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/techclot.com\/index.php\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/techclot.com\/index.php\/wp-json\/wp\/v2\/comments?post=5167"}],"version-history":[{"count":0,"href":"https:\/\/techclot.com\/index.php\/wp-json\/wp\/v2\/posts\/5167\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/techclot.com\/index.php\/wp-json\/wp\/v2\/media\/2336"}],"wp:attachment":[{"href":"https:\/\/techclot.com\/index.php\/wp-json\/wp\/v2\/media?parent=5167"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/techclot.com\/index.php\/wp-json\/wp\/v2\/categories?post=5167"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/techclot.com\/index.php\/wp-json\/wp\/v2\/tags?post=5167"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}